Synonym
Chloramphenicol stearate; Eusynthomycin; Madomicetina; Chloramphenicol monostearate;
IUPAC/Chemical Name
(2R,3R)-2-(2,2-dichloroacetamido)-3-hydroxy-3-(4-nitrophenyl)propyl stearate
InChi Key
IDWDXHQLOMJDRU-XNMGPUDCSA-N
InChi Code
InChI=1S/C29H46Cl2N2O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-26(34)39-22-25(32-29(36)28(30)31)27(35)23-18-20-24(21-19-23)33(37)38/h18-21,25,27-28,35H,2-17,22H2,1H3,(H,32,36)/t25-,27-/m1/s1
SMILES Code
CCCCCCCCCCCCCCCCCC(OC[C@@H](NC(C(Cl)Cl)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
589.59
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: BAGGIO GC. [Modification of utilization of chloramphenicol stearate in relation to age]. Acta Paediatr Lat. 1953 May-Jun;6(3):317-22. Undetermined Language. PubMed PMID: 13147825.
2: BARON A. [Utilization of chloramphenicol stearate in pediatrics]. Acta Pediatr Esp. 1954 Jan;11(133):100-1. Undetermined Language. PubMed PMID: 13147903.
3: Cameroni R, Coppi G, Forni F, Gamberini G, Ferioli V. [Pseudomorphism of chloramphenicol stearate and palmitate in relationship availability]. Farmaco Prat. 1983 Apr;38(4):173-82. Italian. PubMed PMID: 6861978.
4: BARON A. [The use of chloramphenicol stearate in pediatrics]. Acta Pediatr Esp. 1953 Aug;11(128):737-8. Undetermined Language. PubMed PMID: 13113965.
5: CANTARUTTI F. [One year of clinical experience with chloramphenicol stearate]. Acta Paediatr Lat. 1953 May-Jun;6(3):259-70. Undetermined Language. PubMed PMID: 13147820.
6: ALMIRANTE L, DE CARNERI I, COPPI G. [Relation between the therapeutic activity and the crystalline and amorphous state of chloramphenicol stearate]. Farmaco Prat. 1960 Aug;15:471-82. Italian. PubMed PMID: 14448291.
7: Bernabei MT, Coppi G, Cameroni R. [Effect of surfactants on the in vitro enzymatic hydrolysis of chloramphenicol stearate]. Farmaco Prat. 1981 Jun;36(6):294-303. Italian. PubMed PMID: 7274410.
8: Cameroni R, Bernabei MT, Forni F, Coppi G. Polymorphism of chloramphenicol stearate. II - Kinetics of solid-state transition of crystal forms. Farmaco Prat. 1978 Oct;33(10):447-54. PubMed PMID: 750230.
9: Cameroni R, Gamberini G, Forni F, Coppi G, Ferioli V, Bernabei MT. [Polymorphism of chloramphenicol stearate]. Farmaco Prat. 1978;33(4):141-61. Italian. PubMed PMID: 729772.
10: Bernabei MT, Coppi G, Forni F, Cameroni R, Galli E. [Determination of the crystallinity of biologically active polymorph forms of chloramphenicol stearate: correlation with in vitro enzymatic hydrolysis]. Farmaco Prat. 1979 Aug;34(8):338-46. Italian. PubMed PMID: 540661.
11: Forni F, Iannuccelli V, Cameroni R. Surface area and crystallinity of Form A of chloramphenicol palmitic and stearic esters: which one is the limiting factor in the enzymatic hydrolysis? J Pharm Pharmacol. 1987 Dec;39(12):1041-3. PubMed PMID: 2894436.
